Whiterabbit.ai

Redwood City, CA All United States companies → — Founded 2017

Imaging AI Specialist Specialty-Focused AI

Radiology

Oncology AI Radiology & Imaging AI

Later Stage VC (Series C) — $92.5M

Claim this company

Products

WRDensity by Whiterabbit.ai

Whiterabbit.ai

Oncology AI

WRDensity by Whiterabbit.ai is an FDA-cleared, AI-driven software that assists radiologists in accurately and consistently assessing breast density from mammography images, providing ACR BI-RADS categories and improving workflow efficiency.

Contact vendor

See all 1 product →

About Whiterabbit.ai

Whiterabbit.ai is a healthcare AI company dedicated to significantly reducing late-stage cancer diagnoses, beginning with breast cancer, by enabling earlier and more accurate detection. The company develops state-of-the-art artificial intelligence software designed to enhance the entire breast cancer screening process. This includes improving screening rates, boosting radiologist productivity and accuracy, optimizing clinic operations for timely and compassionate patient care, and enhancing patient engagement through innovative tools.

Their product suite includes FDA-cleared solutions like WRDensity, an AI-driven software that assists radiologists in more accurately and consistently assessing breast density, which is crucial for individualized supplemental screening recommendations. Additionally, Whiterabbit.ai offers WRRisk, a clinical decision support software that provides breast cancer risk assessment based on established models, aiding physicians in creating personalized screening regimens and ensuring consistent follow-up. The company’s approach also extends to patient experience, with efforts to streamline scheduling and provide patients with access to their medical images via a mobile app. Whiterabbit.ai collaborates with leading medical institutions and utilizes extensive datasets to advance the application of machine learning in cancer detection.

Focus Areas

early cancer detection breast cancer screening mammography AI-driven compliance radiologist workflow optimization breast density assessment risk assessment patient engagement

Business Intelligence

Key Investors	WRVI Capital, Aceso Technology Partners, RadNet, Hologic, Follow [the] Seed, Guardant Health
Partnerships	RadNet, American College of Radiology (ACR) Data Science Institute, Arterys, Washington University School of Medicine in St. Louis (Mallinckrodt Institute of Radiology), Stanford University
Acquisitions	AZ-TECH RADIOLOGY and OPEN MRI
Technology	AI-driven software, machine learning, deep learning, cloud-native
FDA Clearances	1 cleared products (estimated)

What Physicians Need to Know

Early Cancer Detection & Breast Cancer Screening

Whiterabbit.ai specializes in developing robust AI technologies to improve the speed and accuracy of early cancer detection, with a primary focus on breast cancer. Their mission is to significantly reduce late-stage cancers by detecting them in their earliest stages.

Mammography AI

The company's core technology includes a state-of-the-art AI suite designed to assist radiologists in interpreting mammograms, including digital breast tomosynthesis (3D mammograms). Their deep learning algorithms analyze scans to measure and classify density, detect calcifications, and identify early signs of cancer.

AI-driven Compliance & Patient Engagement

Whiterabbit.ai offers a software program called ACT that uses AI to create individualized patient outreach strategies, combining mammogram reminders and educational information to improve compliance with recommended screening schedules. This aims to increase screening rates and reduce interval cancers.

Radiologist Workflow Optimization

Their AI solutions are designed to streamline clinic workflows, improve radiologists' accuracy and productivity, and reduce false positives without missing cancer cases. This allows radiologists to focus on more questionable scans and reduces unnecessary callbacks and patient anxiety.

Breast Density Assessment

WRDensity is an FDA-cleared AI-driven software that assists radiologists in more accurately and consistently assessing breast density. A longitudinal study showed WRDensity produced 43% more consistent assessments than radiologists over multiple years.

Risk Assessment

WRRisk is a clinical decision support software that assigns a patient risk rating based on established breast cancer risk models. It estimates 10-year and lifetime risk, providing vital information for personalized screening regimens and consistent follow-up recommendations.

Physician Tip

For physicians, Whiterabbit.ai offers tools that significantly enhance diagnostic accuracy and efficiency. Their AI-powered solutions, such as WRDensity and WRRisk, provide objective and consistent data for breast density assessment and personalized risk stratification, leading to more informed clinical decisions and tailored patient management. The AI's ability to identify low-risk mammograms can reduce radiologist workload and decrease unnecessary patient callbacks, thereby improving workflow and reducing patient anxiety. Furthermore, the ACT program supports patient compliance with screening schedules, ensuring more patients receive timely care and potentially reducing late-stage diagnoses. The integration of these tools aims to empower radiologists to deliver more cost-effective, efficient, and accurate services while enhancing the overall patient experience.

Whiterabbit.ai's technology is designed for integration within existing healthcare infrastructures. They have established partnerships with major imaging service providers like RadNet, deploying their platform across numerous clinics. Their solutions, such as WRRisk, integrate seamlessly with PACS systems to deliver real-time feedback. Additionally, they collaborate with leading research institutions, including the Mallinckrodt Institute of Radiology at Washington University School of Medicine and Stanford School of Medicine, to build robust datasets and advance machine learning in cancer detection. WRDensity is also available on the American College of Radiology (ACR) AI-LAB platform, facilitating evaluation and adoption of AI in breast density assessment.

At a glance

Founded 2017

HQ Redwood City, CA · United States

Team size 61

CEO Alexander Sardiña, MD

Funding Later Stage VC (Series C) — $92.5M

FDA clearances 1 (estimated)

Products 1

Products by Whiterabbit.ai

1 product in the directory

WRDensity by Whiterabbit.ai

Whiterabbit.ai

Oncology AI

Contact vendor

What the Web Says

Whiterabbit.ai is a healthcare AI company focused on improving early breast cancer detection through AI-driven solutions and a patient-centric mobile app. Their products, WRDensity and WRRisk, assist radiologists in interpreting mammograms, assessing breast density, and evaluating cancer risk. While specific product reviews on major platforms like G2, Glassdoor, and Capterra are limited for Whiterabbit.ai's healthcare products, general sentiment from employer reviews and related AI discussions suggests a mixed but generally positive outlook on the company's mission and technology.

Overall: Mixed

Strengths

Excellent management and a smart, passionate team.
Good work/life balance for employees.
Great mission to revolutionize healthcare through early cancer detection.
AI-enabled products (WRDensity, WRRisk) enhance diagnostic accuracy and streamline workflows.
WRDensity has demonstrated 43% more consistency than traditional radiologist assessments.
Focus on both technological innovation and patient experience, including a mobile app for patient access to images.

Limitations

Some employee reviews mention bad management, gossip, and favoritism.
Concerns about employees being treated poorly and incentives being threatened.
Lack of paid maternity leave.
Limited public product reviews on major platforms like G2, Glassdoor, and Capterra specifically for Whiterabbit.ai's healthcare AI products.
One review mentions a high-stress environment with micromanagement and lack of progression for some roles.

Based on reviews from: Indeed.com, PromptLoop, PR Newswire, PitchBook, Himalayas, Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about Whiterabbit.ai.

Loading videos...

Videos load interactively. If none appear, search YouTube for Whiterabbit.ai →

View all on YouTube

Press & Coverage

Applied Radiology

AI-Assisted Breast Cancer Screening Could Reduce Follow-Up Tests

A study by Washington University School of Medicine in St. Louis and Whiterabbit.ai suggests that AI can improve breast cancer screening by reducing false positives without missing cancer cases. The research, published in Radiology: Artificial Intelligence, involved an algorithm that identified normal mammograms with high sensitivity, potentially freeing radiologists to focus on more questionable scans.

2024-04

ScienceDaily

AI-assisted breast-cancer screening may reduce unnecessary testing

Researchers from Washington University School of Medicine in St. Louis and Whiterabbit.ai have shown that AI assistance could improve breast cancer screening by reducing false positives. A simulation study demonstrated that AI can reliably identify very low-risk mammograms, leading to fewer callbacks for additional testing while maintaining cancer detection rates.

2024-04

Whiterabbit.ai

Whiterabbit Collaborates with the American College of Radiology to Enable Democratized Access to Artificial Intelligence

Whiterabbit.ai announced a collaboration with the American College of Radiology (ACR) Data Science Institute to make its FDA-cleared AI-driven breast density software, WRDensity, available on ACR's AI-LAB platform. This collaboration aims to expand the reach and adoption of AI applications in healthcare.

2023-11

Whiterabbit.ai

Whiterabbit.ai Announces Call for Radiologists to Participate in Study to Evaluate the Impact of Artificial Intelligence on Radiologists' Performance

Whiterabbit.ai is recruiting mammography radiologists for a retrospective study, in collaboration with Stanford School of Medicine, to evaluate AI's impact on radiologist performance. The study will test the assumption that AI does not influence radiologists' performance.

2023-09

PR Newswire

Whiterabbit, Creator of AI to Improve and Streamline Breast Cancer Diagnoses, Emerges from Stealth to Announce New CEO and FDA Clearance

Whiterabbit emerged from stealth mode, announcing Dr. Alexander Sardiu00f1a as its new CEO and FDA clearance for its first medical software product, WRDensity. The company aims to improve early breast cancer detection through AI-driven compliance and enhanced diagnostic tools.

2021-05

AuntMinnie

Whiterabbit gets FDA nod for breast density AI software

Whiterabbit received FDA clearance for its WRDensity breast density analysis software, designed to provide objective data for radiologists. This clearance, along with the appointment of a new CEO, marks the company's emergence from stealth mode.

2021-05

Imaging Technology News (ITN)

Breast Cancer AI Company Whiterabbit Receives FDA Clearance for WRDensity

Whiterabbit, an AI technology company focused on early breast cancer detection, announced FDA clearance for its WRDensity product and the appointment of Alexander Sardiu00f1a, M.D., as CEO. The company's AI technology aims to increase breast cancer screening compliance and empower radiologists.

2021-05

accessdata.fda.gov

Whiterabbit.ai Inc. 510(k) Premarket Notification

The FDA reviewed Whiterabbit.ai Inc.'s 510(k) premarket notification and determined their device, WRDensity, is substantially equivalent to legally marketed predicate devices. This allows Whiterabbit.ai to market the device subject to general controls provisions.

2020-10

Frequently Asked Questions

How does Whiterabbit.ai's technology specifically enhance early breast cancer detection and improve mammography screening outcomes?

Whiterabbit.ai aims to improve early cancer detection by increasing patient compliance with screening schedules and providing AI-supported tools for radiologists. Their AI helps identify normal mammograms with high sensitivity, which can reduce false positives and unnecessary callbacks without missing cancer cases, thereby improving overall screening efficiency and patient experience.

How does Whiterabbit.ai's AI integrate into existing radiologist workflows, and what specific tools does it offer for breast density and risk assessment?

Whiterabbit.ai offers WRDensity, an FDA-cleared AI software that assists radiologists in accurately and consistently assessing breast density, and WRRisk, a clinical decision support tool for breast cancer risk assessment based on established models. These tools are designed to integrate seamlessly into existing radiologist workstations, providing relevant information in context to support personalized screening recommendations and improve diagnostic accuracy.

How does Whiterabbit.ai help healthcare facilities ensure compliance with evolving breast cancer screening guidelines and regulations?

Whiterabbit.ai's ACT product is an AI-powered service that enhances patient compliance with annual mammogram recommendations through personalized outreach strategies, including reminders and educational content. This system helps healthcare facilities meet screening guidelines by significantly increasing patient adherence and can also help manage increased patient volumes by distributing appointments evenly throughout the year.

What are Whiterabbit.ai's solutions for improving patient engagement and adherence to screening protocols?

Whiterabbit.ai's ACT program utilizes AI to create individualized patient outreach strategies, employing a combination of email, text, phone calls, and push notifications to motivate patients to schedule and complete their screenings. This patient-centric approach aims to increase screening compliance and reduce patient anxiety by streamlining the scheduling process and providing valuable breast health education.

What is the typical pricing model for Whiterabbit.ai's solutions, and what kind of implementation support and ongoing partnerships can we expect?

While specific pricing models are not publicly detailed, Whiterabbit.ai's solutions are offered as AI-powered software and services. They emphasize ease of integration with existing EMR and RIS databases, typically requiring read-only access for implementation. Whiterabbit.ai has established significant partnerships with major imaging providers like RadNet, as well as academic institutions such as Washington University and Stanford, indicating robust industry collaboration and support for their deployments.

What is Whiterabbit.ai's current market position, and what are its long-term plans or recent achievements that indicate company stability and future growth?

Whiterabbit.ai is a privately held AI technology company focused on making late-stage diseases a rarity, particularly in breast cancer, with FDA-cleared products like WRDensity. They have strong partnerships with large imaging providers such as RadNet and collaborations with the American College of Radiology, demonstrating a solid market presence and commitment to expanding AI adoption in healthcare. Their AI has been trained on over 11 million data points, serving more than 2 million patients, and they continue to develop next-generation AI solutions.

Related Companies

Suggest an Edit →